Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Total Liabilities

Everything the company owes to creditors and other parties.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Total Liabilities · Q2 FY2026 · quarter ended Mar 2026

Total liabilities falls 13.7% from a year ago

Total liabilities stood at $198.12M at the end of Q2 FY2026, down 13.7% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Total liabilities amounted to 63.0% of total assets at the end of Q2 FY2026, down 8.1 pp from a year earlier.
  • Total liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total liabilities keeps falling in the next quarterly balance sheet after a -13.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$198.12M-2.4% QoQ
Last fiscal yearSep 2025
$216.02M-12.8% YoY
Year agoMar 2025
$229.46M-13.7% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.7%——
1 year-12.8%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
216.02M USD
Year-over-year change
-12.8%
4-year CAGR
+51.1%

Total Liabilities vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's Mar 2026 total liabilities of $198.12M is the 3rd highest of the 11 companies compared; the peer median is $41.28M.
  • Its year-over-year change of -13.7% is the 8th highest of 11, against a peer median of +0.6%.
  • Total liabilities amounts to 63.0% of total assets for ENTA, versus a peer median of 21.1%.
ENTA Competitors Peer median
Total Liabilities for ENTA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$8.29B +93713.8%+2.6%3.9%
FHTXFoghorn Therapeutics Inc.Mar 2026$298.58M -6.8%-8.8%134.4%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$198.12M -13.7%+53.9%63.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$59.46M +56.1%+42.6%49.7%
CRBUCaribou Biosciences, Inc.Mar 2026$46.98M -16.8%-10.0%31.5%
VYGRVoyager Therapeutics, Inc.Mar 2026$45.66M -43.3%-17.6%20.8%
ASMBAssembly Biosciences, Inc.Mar 2026$36.9M -48.7%+38.5%15.7%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$33.37M +15.5%+15.0%12.5%
NAUTNautilus Biotechnology, Inc.Mar 2026$33.36M +0.3%-0.9%18.8%
PYXSPyxis Oncology, Inc.Mar 2026$33.03M +0.8%-9.0%51.4%
TNYATenaya Therapeutics, Inc.Mar 2026$28.88M +17.6%-12.7%21.4%
Peer median (excluding ENTA) $41.28M+0.6%-4.9%21.1%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents57.21M43.99M85.39M37.23M32.3M
Short-term Investments186.8M205.24M284.52M210.95M156.57M
Net Receivables60.83M49.04M39.62M38.65M6.88M
Inventory00000
Other Current Assets0013.26M608K8.59M
Total Current Assets319.02M311.71M422.79M299.85M204.34M
Property, Plant & Equipment (Net)10.65M29.75M34.71M73.35M72.94M
Goodwill00000
Intangible Assets00000
Long-term Investments109.02M33.25M3.97M3.36M3.36M
Tax Assets2.07M5.18M000
Other Non-current Assets92K696K803K94K92K
Total Non-current Assets121.84M68.88M39.48M76.8M76.4M
Total Assets440.86M380.59M462.28M376.65M280.73M
Account Payables9.54M6M4.1M8M1.95M
Short-term Debt00034.46M30.71M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities16.34M14.5M35.08M00
Total Current Liabilities36.17M29.83M62.79M57.54M48.56M
Long-term Debt1.51M1.42M0136.13M112.44M
Deferred Tax Liabilities2.07M5.18M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities558K454K161.52M231K260K
Total Non-current Liabilities5.26M29.43M182.75M190.3M167.46M
Total Liabilities41.43M59.26M245.54M247.84M216.02M
Common Stock202K208K211K212K214K
Retained Earnings48.58M(73.18M)(207M)(323.04M)(404.93M)
Accumulated OCI(382K)(3.72M)(1.17M)302K(339K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity399.43M321.33M216.74M128.81M64.72M
Total Debt6.84M26.69M26.51M226.06M201.06M
Net Debt(50.37M)(17.31M)(58.88M)188.83M168.76M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.